---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-012339"
form_type: "8-K"
ticker: "DNA"
cik: "0001830214"
company_name: "Ginkgo Bioworks Holdings, Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:46:51.546681+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ginkgo Q4 revenue $33M (-24% YoY); announces biosecurity spin-off, FY2026 cash burn guidance $150-125M

## Summary
- Q4 2025 total revenue $33M, down 24% YoY; Cell Engineering $26M (-26%), Biosecurity $7M (-22%).
- GAAP net loss $(81)M improved from $(108)M; Adjusted EBITDA $(36)M vs $(57)M.
- Full year 2025 revenue $170M (-25%); GAAP net loss $(313)M; Adjusted EBITDA $(167)M; cash $423M.
- Announced divestiture of biosecurity business to investor consortium for minority equity stake; expected close H1 2026.
- Strategic focus on autonomous labs; decommissioning lab benches; collaborations with OpenAI and PNNL ($47M contract). FY2026 cash burn guidance $(150)-$(125)M.

## SEC filing metadata
- accession: 0001628280-26-012339
- form_type: 8-K
- ticker: DNA
- cik: 0001830214
- company_name: Ginkgo Bioworks Holdings, Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1830214/000162828026012339/0001628280-26-012339-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1830214/000162828026012339/dna-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-012339
- JSON: https://secwatch.observer/filing/0001628280-26-012339.json
- Plain text: https://secwatch.observer/filing/0001628280-26-012339.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.